BlackRock Health Sciences Term Trust (NYSE: BMEZ) is a closed-end management investment company organized as a Delaware statutory trust. Launched in March 2020, BMEZ seeks to provide total return through a combination of current income and capital appreciation by investing primarily in equity and equity-related securities of companies in the health sciences sector. The trust is structured with a fixed termination date in October 2030, at which time shareholders will vote on its liquidation, extension or conversion.
The fund’s investment portfolio is diversified across subsectors within health sciences, including biotechnology, pharmaceuticals, medical devices, diagnostics and healthcare services. Utilizing BlackRock’s fundamental research platform, BMEZ takes both long and, when appropriate, short positions to manage risk and potentially enhance returns. The trust may also employ leverage and derivatives to pursue its investment objectives, subject to its board-approved guidelines.
As a product of BlackRock, Inc., the world’s largest asset manager, BMEZ benefits from the firm’s extensive health sciences research capabilities and global distribution network. Portfolio management is led by a team of seasoned health sciences specialists at BlackRock Advisors, who leverage the firm’s proprietary analytics and risk management infrastructure. Oversight is provided by an independent board of trustees, ensuring that the trust adheres to its stated strategy and governance standards.
AI Generated. May Contain Errors.
